Latin America held a 3% share of the market in 2025 and is expected to grow at a significant CAGR of 14% during the projection period, driven by GLP-1 medications that are driving structural health and economic shifts across Latin America by curbing surging obesity and type-2 diabetes rates, spurring vast biopharma investments, and fundamentally changing consumer habits in the fast-moving consumer goods sector
: [12] EGR1 , [2] - [4] PMC 2025 : BPC-157 , , , , , , , [5]
IV Carnitine Therapy is explored for its potential to: Boost energy levels and reduce fatigue
64 DumanC
Structural Modification 2: Preserved Disulfide Bridge The Cys2-Cys7 Bond Is Retained Native amylin contains a disulfide bridge between cysteine residues at positions 2 and 7 at the N-terminus of the peptide
As you add more fiber to your mealsespecially combined with protein and a bit of healthy fatyou slow down digestion and prolong the feeling of fullness